2-benzoyloxy-propane-1,2,3-tricarboxylic acid | 91903-88-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-benzoyloxy-propane-1,2,3-tricarboxylic acid
• 英文别名: 2-Benzoyloxy-propan-1,2,3-tricarbonsaeure；2-Benzoyloxypropane-1,2,3-tricarboxylic acid
• CAS: 91903-88-7
• 化学式: C₁₃H₁₂O₈
• 分子量: 296.233
• InChiKey: XWZUUVHBEQPVJM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  138
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  苯甲酰氯 、 柠檬酸 生成 2-benzoyloxy-propane-1,2,3-tricarboxylic acid
  参考文献：
  名称：

  Smith, Zeitschrift fur Physikalische Chemie (Leipzig), 1936, vol. 177, p. 131,149

  摘要：

  DOI：

文献信息

• [EN] 4-ARYL-BUTANE-1,3-DIAMIDES<br/>[FR] 4-ARYLBUTANE-1,3-DIAMIDES
  申请人：NOVARTIS AG

  公开号：WO2010086366A1

  公开（公告）日：2010-08-05

  The invention relates to compound of the formula (I) in which the substituents are as defined in the specification; m free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

  这项发明涉及式(I)的化合物，其中取代基如规范中定义；m自由形式或盐形式；其制备，作为药物的用途以及包含它的药物。
• CDK-INHIBITING PYRROLOPYRIMIDINONE CARBOXAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING HEPATOCELLULAR CARCINOMA
  申请人：Lee Seung Ki

  公开号：US20130237495A1

  公开（公告）日：2013-09-12

  The present invention relates to a CDK-inhibiting pyrrolopyrimidinone carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing same as an active ingredient for preventing or treating liver cell cancer, and the composition containing the pyrrolopyrimidinone carboxamide derivative of the present invention suppresses the cell growth of SNU-354 cell, which is a liver cancer stem cell in humans, by inhibiting CDK1 and CDK2, and induces cell apoptosis of the cell by inhibiting CDK7 and CDK 7, and thus can be effective in use for preventing or treating liver cell cancer.

  本发明涉及一种CDK抑制吡咯吡嘧啶酮羧酰胺衍生物或其药用可接受的盐，以及含有该衍生物作为活性成分的药物组合物，用于预防或治疗肝细胞癌，本发明的吡咯吡嘧啶酮羧酰胺衍生物组合物通过抑制CDK1和CDK2抑制SNU-354细胞（人类肝癌干细胞）的细胞生长，并通过抑制CDK7和CDK7诱导细胞凋亡，从而可有效用于预防或治疗肝细胞癌。
• Novel $g(a)-amino-n-(diaminophosphinyl) lactam derivative
  申请人：Abe Masatoshi

  公开号：US20050164989A1

  公开（公告）日：2005-07-28

  There are disclosed a novel α-amino-N-(diaminophosphinyl)lactam derivative represented by general formula (1): wherein, for example, A is a hydrogen atom or a substituent such as a lower alkyl group or the like; W, X, Y and Z are independently a hydrogen atom or a substituent such as a lower alkyl group, aryl group, arylacyl group, arylaminocarbonyl group or the like; and Q is —(CH 2 ) n — wherein n is 0 to 3, or its salt, and a therapeutic agent and a prophylactic agent for myelosuppression, a therapeutic agent for infectious diseases, an agent for increasing the number of leukocytes and a dipeptidyl peptidase IV inhibitor which comprise the above-mentioned derivative or salt thereof as an active ingredient.

  公开了一种新型α-氨基-N-(二氨基膦基)内酰胺衍生物，其通式表示为(1):其中，例如，A是氢原子或取代基，例如较低的烷基或类似物; W、X、Y和Z分别是氢原子或取代基，例如较低的烷基、芳基、芳基酰基、芳基氨基甲酰基或类似物; Q是—(CH2)n—，其中n为0到3，或其盐，并且包括上述衍生物或其盐作为活性成分的治疗剂和预防剂，用于骨髓抑制、传染病治疗剂、增加白细胞数的剂和二肽基肽酶IV抑制剂。
• Heterocyclic compounds
  申请人：——

  公开号：US20040147546A1

  公开（公告）日：2004-07-29

  A pharmaceutical composition containing a heterocyclic compound of the formula (I) 1 wherein each symbol is as defined in the specification, an isomer thereof, a solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient has a superior TNF-&agr; production suppressing action. Accordingly, it is useful for the prophylaxis or treatment of various diseases caused by abnormal production of TNF-&agr;.

  一种含有式 (I) 杂环化合物的药物组合物 1 其中各符号如说明书中所定义）的杂环化合物、其异构体、其溶液或其药学上可接受的盐作为活性成分的药物组合物，具有优异的 TNF-&agr; 生成抑制作用。因此，它可用于预防或治疗由 TNF-&agr; 异常产生引起的各种疾病。
• NOVEL ALPHA-AMINO-N-(DIAMINOPHOSPHINYL)LACTAM DERIVATIVE
  申请人：NIPPON KAYAKU KABUSHIKI KAISHA

  公开号：EP1489088B1

  公开（公告）日：2008-08-13